MYLAN-ACYCLOVIR 400 MG
ACYCLOVIR : 400 MG · DIN 02242463 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-ACYCLOVIR?
MYLAN-ACYCLOVIR 400 MG contains ACYCLOVIR : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02242463, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Dec-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-ACYCLOVIR used for?
Treatment of initial episodes of herpes genitalis; suppression of frequent recurrences; acute treatment of herpes zoster (shingles) and varicella (chickenpox).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242463 |
|---|---|
| Brand name | MYLAN-ACYCLOVIR |
| Generic / active ingredient | ACYCLOVIR : 400 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AB01 ACYCLOVIR |
| AHFS class | 56:28.36 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Dec-2009 |
| Original market date | 2001-02-22 00:00:00 |
How is it administered?
Genital herpes: 200mg 5x/day. Zoster: 800mg 5x/day for 7-10 days. Chickenpox: 20mg/kg (max 800mg) 4x/day for 5 days. Adjust dose in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
(Not explicitly stated in provided text sections, though section 14 is titled STORAGE AND STABILITY).
How is it supplied?
200, 400 and 800 mg Tablets (Specific container types not listed in provided text).
Contraindications
Hypersensitivity to acyclovir, valacyclovir, or any components of the formulation.
Warnings and precautions
Maintain adequate hydration. Risk of TTP/HUS in immunocompromised patients. Renal insufficiency/failure observed. Neurological side effects possible, especially in elderly/renally impaired.
Is ACYCLOVIR in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AURO PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J05AB01 ACYCLOVIR. 15 of 48 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACYCLOVIR SODIUM INJECTION | 50 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02494558 |
| ACYCLOVIR SODIUM INJECTION | 50 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02236926 |
| ACYCLOVIR SODIUM INJECTION | 50 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02531224 |
| APO-ACYCLOVIR | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 02207621 |
| APO-ACYCLOVIR | 400 MG | TABLET | APOTEX INC | MARKETED | DIN 02207648 |
| APO-ACYCLOVIR | 800 MG | TABLET | APOTEX INC | MARKETED | DIN 02207656 |
| MINT-ACYCLOVIR | 200 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02524708 |
| MINT-ACYCLOVIR | 400 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02524716 |
| MINT-ACYCLOVIR | 800 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02524724 |
| MYLAN-ACYCLOVIR | 200 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02242784 |
Who else supplies ACYCLOVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ACYCLOVIR appears in 314 registered pack listings across 12 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.